ProPhase Labs (PRPH) details COVID-19 receivables and Chapter 11 update

Rhea-AI Filing Summary

ProPhase Labs, Inc. filed a current report to share that it has issued a new press release about its efforts to recover legacy COVID-19 testing receivables. The update focuses on the Company’s Crown Medical Collections initiative, which is working on amounts owed to its laboratory subsidiaries that are currently in Chapter 11 proceedings. The press release, dated January 26, 2026, is attached as an exhibit to the report, providing more detail on the operational progress of this collection effort.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0000868278 0000868278 2026-01-26 2026-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 26, 2026

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

Delaware		000-21617		23-2577138
(State or other jurisdiction of incorporation )		(Commission File Number)		(I.R.S. Employer Identification No.)

626 RXR Plaza, 6th Floor Uniondale, New York		11556
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (516) 989-0763

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14(d)-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Trading Symbol		Name of Each Exchange of Which Registered
Common Stock, par value $0.0005		PRPH		OTC ID

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

The Securities and Exchange Commission requires disclosure of material changes and events that the registrant deems of importance to security holders via Form 8-K filings. On January 26, 2026, ProPhase Labs, Inc. (“The Company”) issued a press release providing an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings.

A copy of the press release is furnished as Exhibit 1.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

1.1	Press Release dated January 26, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.
By:	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
Date: Tuesday, January 27, 2026

FAQ

What did ProPhase Labs (PRPH) report in this 8-K filing?

ProPhase Labs reported that it issued a press release providing an operational update on its Crown Medical Collections initiative related to legacy COVID-19 testing receivables.

What is the focus of ProPhase Labs’ Crown Medical Collections initiative?

The Crown Medical Collections initiative focuses on collecting legacy COVID-19 testing receivables held by ProPhase Labs’ laboratory subsidiaries that are in Chapter 11 proceedings.

When did ProPhase Labs issue the press release about the collection initiative?

ProPhase Labs issued the press release on January 26, 2026, and it is attached to the report as Exhibit 1.1.

Which ProPhase Labs subsidiaries are involved in the COVID-19 receivables update?

The update relates to laboratory subsidiaries of ProPhase Labs that currently hold legacy COVID-19 testing receivables and are in Chapter 11 proceedings.

Where can investors find more detail on ProPhase Labs’ receivables update?

More detail is available in the press release furnished as Exhibit 1.1 to the report, which provides the operational update on the Crown Medical Collections initiative.

What exhibit numbers are included with this ProPhase Labs 8-K?

The report includes Exhibit 1.1, the press release dated January 26, 2026, and Exhibit 104, the cover page interactive data file.